| TA129 |
Multiple myeloma - bortezomib (TA129) |
|
-
-
Bortezomib monotherapy for relapsed multiple myeloma
This guidance recommends bortezomib monotherapy as a possible treatment for progressive multiple myeloma for people:
- whose multiple myeloma has relapsed for the first time after having one treatment, and
- who have had a bone marrow transplant, unless it is not suitable for them.
- After not more than four cycles of treatment, a blood or urine test should be done to check how well the cancer has responded to bortezomib.
- Treatment should be continued only if there has been at least a partial response to the drug.
-
Other information
How this guidance was produced
Background information
This page was last updated: 12 December 2011
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
